Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term mammalian target. Found 10 abstracts

Lee CK, Marschner IC, Simes RJ, Voysey M, Egleston B, Hudes G, de Souza P. Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus. Clinical Cancer Research. 2012 Jun;18(11):3188-96.   PMCID: Not NIH funded
Ni MJ, MacFarlane AW, Toft M, Lowell CA, Campbell KS, Hamerman JA. B-cell adaptor for PI3K (BCAP) negatively regulates Toll-like receptor signaling through activation of PI3K. Proceedings of the National Academy of Sciences of the United States of America. 2012 Jan;109(1):267-72.   PMCID: PMC3252908
Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study. Gynecologic Oncology. 2011 Oct;123(1):19-26.   PMCID: PMC3336961 [Available on 2012/10/1]
Makhlin I, Zhang J, Long CJ, Devarajan K, Zhou Y, Klein-Szanto AJ, Huang M, Chernoff J, Boorjian SA. The mTOR pathway affects proliferation and chemosensitivity of urothelial carcinoma cells and is upregulated in a subset of human bladder cancers. BJU international. 2011 Jul;108(2B):E84-E90.   PMCID: PMC3116980
Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G. Analysis of PTEN and HIF-1 alpha and Correlation With Efficacy in Patients With Advanced Renal Cell Carcinoma Treated With Temsirolimus Versus Interferon-alpha. Cancer. 2009 Aug;115(16):3651-60.   PMCID: not NIH funded
Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T. mTOR Is a Promising Therapeutic Target Both in Cisplatin-Sensitive and Cisplatin-Resistant Clear Cell Carcinoma of the Ovary. Clinical Cancer Research. 2009 Sep;15(17):5404-13.   PMCID: PMC2743856
Astrinidis A, Henske EP. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene. 2005 Nov 14;24(50):7475-81.
Ruggero D, Sonenberg N. The Akt of translational control. Oncogene. 2005 Nov 14;24(50):7426-34.
van Slegtenhorst M, Mustafa A, Henske EP. Pas1, a G(1) cyclin, regulates amino acid uptake and rescues a delay in G(1) arrest in Tsc1 and Tsc2 mutants in Schizosaccharomyces pombe. Human molecular genetics. 2005 Oct;14(19):2851-8.
Henske EP. The genetic basis of kidney cancer: Why is tuberous sclerosis complex often overlooked?. Current Molecular Medicine. 2004 Dec;4(8):825-31.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term mammalian target

mammalian target expression rapamycin cancer AKT mTOR in-vitro disease pathway phase-iii trial 3-kinase mtor akt pathway tumor-suppressor gene cell-growth eif4e gene amplification renal angiomyolipomas protein-kinase-b cancer-cells inflammatory response b-raf kinase metastatic colorectal-cancer therapeutic target bladder cancer mouse model Akt complex mtor inhibitor cap-dependent translation 1989 entice rl-statistics in medicine-v8-p431 in-vivo chemotherapy somatic mutations ovarian cell lung-carcinoma rheb binds therapeutic strategy therapy initiation-factor 4e mutational analysis PKB growth suppressor progression antitumor-activity tsc2 gene Rheb platinum-resistant p70 s6 kinase breast-cancer engagement growth refractory human breast-tumors tsc2 gap activity akt ribosome biogenesis surrogate prognostic-factors Ovarian clinical trial phosphatidylinositol 3-kinase apoptosis lymphangiomyomatosis resistant prostate-cancer lipopolysaccharide PI3K pathway tuberous sclerosis complex gynecologic-oncology-group kappa-b translation control radical cystectomy arginine uptake renal-cell carcinoma mammalian target of Rapamycin Circulating tumor cells signaling pathway protein metabolism fission yeast canavanine resistance carcinoma patients peripheral-blood adenocarcinoma dendritic cells inhibition inhibitor rad001 hippel-lindau-disease s6 kinase activation pulmonary lymphangioleiomyomatosis end-points eIF4E messenger-rna translation innate immunity clinical-trials phosphoinositide 3-kinase advanced renal cell carcinoma molecular targeted therapies-temsirolimus-molecular markers hogg-dube-syndrome management induced epithelioid angiomyolipoma macrophages tyrosine kinase inhibitor cisplatin tuberous sclerosis gene inhibitor
Last updated on Wednesday, February 05, 2020